Investors | Novartis
Novartis' Cosentyx receives MHRA approval for two types of juvenile idiopathic arthritis - PMLiVE
Novartis' Zykadia nears first-line lung cancer label - PMLiVE
Novartis sells phase 3 rare disease drug to Pharming | Fierce Biotech
Novartis signs deal with BeiGene to bolster immunotherapy pipeline
Novartis to prioritise U.S. market, unfazed by drug pricing pushback | Reuters
A World of Opportunity
Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer
Rick Carlson - Oncology Care Consultant (Breast Cancer) - Novartis | LinkedIn
Novartis's nuclear vision starts to take shape | Evaluate
Six Former and Current Novartis AG Execs Charged With Bribing Doctors in Korea | BioSpace
Novartis hi-res stock photography and images - Page 13 - Alamy
Novartis is shutting down Colorado plant, laying off 400 employees after overestimating gene therapy demand | Fierce Pharma
Alcon becomes a separately traded standalone company | Novartis
NOVN: Novartis AG Stock Price Quote - SIX Swiss Ex - Bloomberg
Two Children Die After Receiving Novartis Gene Therapy | The Scientist Magazine®
Six Novartis Korea Managers Indicted Over Illegal Payments to Doctors - WSJ
Drug used to treat advanced prostate cancer in short supply, Novartis says - CBS News
Cause and Effect | SIX
Novartis - YouTube
